oncology

Aethlon Medical's Hemopurifier device advances to final clinical trial phase following positive safety review with no adverse events reported.

iDEL Therapeutics appoints Dr. Claudia Ulbrich as Board Chair and secures €9M seed funding led by BiomedVC to advance its novel cancer drug delivery platform.

Pfizer and UnitedHealth Group present buying opportunities for $500 investors. Pfizer trades at 9x forward earnings with oncology growth plans; UnitedHealth at 15x after cost-cutting initiatives.

HUTCHMED initiates Phase III trial of HMPL-760 for relapsed/refractory lymphoma in China, enrolling 240 patients following positive Phase II results.

Novartis acquires SNV4818, a next-gen PI3Kα inhibitor, from Synnovation for $2B upfront plus $1B milestones to treat PIK3CA-mutated breast cancer.

Institutional investors rotate capital to precision oncology biotech as patent cliff pressures Big Pharma. Five clinical-stage companies positioned for M&A amid $303B market opportunity.

Three healthcare stocks under $50 offer distinct value: Pfizer at $27.45 with 9x P/E and strong oncology pipeline; Novo Nordisk at $38.43 capitalizing on weight-loss drugs; Exelixis at $41.80 with proven oncology franchise.

CytomX Therapeutics prices $250M stock offering at $5.30/share to fund Varseta-M development and pipeline advancement, closing March 2026.

Cormorant Asset Management exited its $63.63M Arcellx stake in Q4, missing an 80% year-to-date rally capped by Gilead Sciences' $7.8B acquisition announcement.

Relmada Therapeutics to report Q4 2025 results March 19, 2026, following $160M oversubscribed fundraise and Leerink Partners conference presentation.

Pfizer and Novo Nordisk trade at 9x-10.5x forward earnings with deep pipelines offering long-term value potential despite recent underperformance.

Pfizer's Neumega faces robust growth through 2030 driven by rising cancer diagnoses, chemotherapy intensification, and expanding oncology infrastructure globally.

Pegasys market projected for growth via rising hepatitis B prevalence and indication expansion, though direct-acting antivirals and tariff pressures pose challenges. Asia-Pacific represents fastest-growing region.

Kyntra Bio will report fourth quarter and full year 2025 financial results on March 16, 2026, as the biopharmaceutical company advances its oncology and rare disease pipeline.

Tempus AI expands multi-year partnership with Merck to develop AI-driven precision medicine biomarkers, though stock declined 1.56% amid broader market weakness.

Exelixis secures FDA approval for zanzalintinib and expands beyond cabozantinib with robust pipeline, posting 57.9% EPS growth while advancing multiple Phase 3 trials.

Pfizer's Braftovi receives full FDA approval for treating BRAF-mutated metastatic colorectal cancer when combined with cetuximab and chemotherapy, based on Phase 3 trial data.

Advanced drug delivery systems market projected to grow from $299.6B (2025) to $487.4B (2030), driven by chronic diseases, nanotechnology breakthroughs, and oncology applications.

Gilead acquires oncology firm Arcellx for $7.8 billion in cash, adding CAR T-cell cancer therapy to its pipeline. Deal expected to close Q4 2024.

Prime Medicine will present at three major biotech conferences in March 2026, including TD Cowen and Citizens Life Sciences, with webcasts available afterward.